US10154990 — Medicaments for the treatment or prevention of fibrotic diseases
Method of Use · Assigned to Boehringer Ingelheim International GmbH · Expires 2026-01-08 · 0y expired
What this patent protects
This patent protects the use of indolinones, specifically those substituted in the 6 position, as a medicament for preventing or treating fibrotic diseases.
USPTO Abstract
The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R 1 to R 5 and X are defined as in claim 1 , the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2620 |
— | nintedanib-esylate |
U-2620 |
— | nintedanib-esylate |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.